Dimensional Fund Advisors LP Raises Position in Agile Therapeutics, Inc. (AGRX)

Dimensional Fund Advisors LP increased its position in shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) by 604.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 95,820 shares of the specialty pharmaceutical company’s stock after purchasing an additional 82,213 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.33% of Agile Therapeutics worth $359,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Franklin Resources Inc. increased its position in shares of Agile Therapeutics by 39.2% during the second quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock worth $10,396,000 after purchasing an additional 780,578 shares in the last quarter. Royce & Associates LP increased its position in shares of Agile Therapeutics by 1.1% during the second quarter. Royce & Associates LP now owns 998,582 shares of the specialty pharmaceutical company’s stock worth $3,745,000 after purchasing an additional 11,000 shares in the last quarter. LMR Partners LLP purchased a new stake in shares of Agile Therapeutics during the second quarter worth approximately $211,000. Finally, Janney Montgomery Scott LLC purchased a new stake in shares of Agile Therapeutics during the second quarter worth approximately $122,000. Hedge funds and other institutional investors own 72.96% of the company’s stock.

AGRX has been the subject of several research reports. Janney Montgomery Scott reiterated a “buy” rating and set a $13.00 price target (down from $15.00) on shares of Agile Therapeutics in a research report on Thursday, August 24th. ValuEngine cut Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Royal Bank Of Canada boosted their price target on Agile Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, September 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $8.00 price target on shares of Agile Therapeutics in a research report on Thursday, September 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Agile Therapeutics in a research report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Agile Therapeutics currently has a consensus rating of “Buy” and an average price target of $10.20.

Agile Therapeutics, Inc. (NASDAQ AGRX) opened at $4.88 on Wednesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.10 and a quick ratio of 4.10. Agile Therapeutics, Inc. has a 12 month low of $1.82 and a 12 month high of $7.06.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.03. sell-side analysts predict that Agile Therapeutics, Inc. will post -0.99 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/12/06/dimensional-fund-advisors-lp-raises-position-in-agile-therapeutics-inc-agrx.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Want to see what other hedge funds are holding AGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agile Therapeutics, Inc. (NASDAQ:AGRX).

Institutional Ownership by Quarter for Agile Therapeutics (NASDAQ:AGRX)

What are top analysts saying about Agile Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agile Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit